Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4.

Hanley, Christopher J; Mellone, Massimiliano; Ford, Kirsty; Thirdborough, Steve M; Mellows, Toby; Frampton, Steven J; Smith, David M; Harden, Elena; Szyndralewiez, Cedric; Bullock, Marc; Noble, Fergus; Moutasim, Karwan A; King, Emma V; Vijayanand, Pandurangan; Mirnezami, Alex H; Underwood, Timothy J; Ottensmeier, Christian H; Thomas, Gareth J

Hanley, Christopher J; Mellone, Massimiliano; Ford, Kirsty; Thirdborough, Steve M; Mellows, Toby; Frampton, Steven J; Smith, David M; Harden, Elena; Szyndralewiez, Cedric; Bullock, Marc; Noble, Fergus; Moutasim, Karwan A; King, Emma V; Vijayanand, Pandurangan; Mirnezami, Alex H; Underwood, Timothy J; Ottensmeier, Christian H; Thomas, Gareth J.

Afiliación

Hanley CJ; Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton, UK; Genkyotex SA, Plan-les-Ouates, Switzerland; La Jolla Institute for Allergy and Immunology, La Jolla, CA.
Mellone M; Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton, UK; Genkyotex SA, Plan-les-Ouates, Switzerland; La Jolla Institute for Allergy and Immunology, La Jolla, CA.
Ford K; Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton, UK; Genkyotex SA, Plan-les-Ouates, Switzerland; La Jolla Institute for Allergy and Immunology, La Jolla, CA.
Thirdborough SM; Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton, UK; Genkyotex SA, Plan-les-Ouates, Switzerland; La Jolla Institute for Allergy and Immunology, La Jolla, CA.
Mellows T; Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton, UK; Genkyotex SA, Plan-les-Ouates, Switzerland; La Jolla Institute for Allergy and Immunology, La Jolla, CA.
Frampton SJ; Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton, UK; Genkyotex SA, Plan-les-Ouates, Switzerland; La Jolla Institute for Allergy and Immunology, La Jolla, CA.
Smith DM; Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton, UK; Genkyotex SA, Plan-les-Ouates, Switzerland; La Jolla Institute for Allergy and Immunology, La Jolla, CA.
Harden E; Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton, UK; Genkyotex SA, Plan-les-Ouates, Switzerland; La Jolla Institute for Allergy and Immunology, La Jolla, CA.
Szyndralewiez C; Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton, UK; Genkyotex SA, Plan-les-Ouates, Switzerland; La Jolla Institute for Allergy and Immunology, La Jolla, CA.
Bullock M; Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton, UK; Genkyotex SA, Plan-les-Ouates, Switzerland; La Jolla Institute for Allergy and Immunology, La Jolla, CA.
Noble F; Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton, UK; Genkyotex SA, Plan-les-Ouates, Switzerland; La Jolla Institute for Allergy and Immunology, La Jolla, CA.
Moutasim KA; Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton, UK; Genkyotex SA, Plan-les-Ouates, Switzerland; La Jolla Institute for Allergy and Immunology, La Jolla, CA.
King EV; Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton, UK; Genkyotex SA, Plan-les-Ouates, Switzerland; La Jolla Institute for Allergy and Immunology, La Jolla, CA.
Vijayanand P; Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton, UK; Genkyotex SA, Plan-les-Ouates, Switzerland; La Jolla Institute for Allergy and Immunology, La Jolla, CA.
Mirnezami AH; Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton, UK; Genkyotex SA, Plan-les-Ouates, Switzerland; La Jolla Institute for Allergy and Immunology, La Jolla, CA.
Underwood TJ; Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton, UK; Genkyotex SA, Plan-les-Ouates, Switzerland; La Jolla Institute for Allergy and Immunology, La Jolla, CA.
Ottensmeier CH; Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton, UK; Genkyotex SA, Plan-les-Ouates, Switzerland; La Jolla Institute for Allergy and Immunology, La Jolla, CA.
Thomas GJ; Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton, UK; Genkyotex SA, Plan-les-Ouates, Switzerland; La Jolla Institute for Allergy and Immunology, La Jolla, CA.

J Natl Cancer Inst ; 110(1)2018 01 01.

Article en En | MEDLINE | ID: mdl-28922779

Asunto(s)

Adenocarcinoma/tratamiento farmacológico; Fibroblastos Asociados al Cáncer/patología; Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico; Carcinoma de Células Escamosas/tratamiento farmacológico; Neoplasias Colorrectales/química; Neoplasias Esofágicas/tratamiento farmacológico; Neoplasias Pulmonares/tratamiento farmacológico; Neoplasias de la Boca/química; Miofibroblastos/patología; NADPH Oxidasas/antagonistas & inhibidores; Neoplasias Orofaríngeas/química; Actinas/análisis; Adenocarcinoma/química; Adenocarcinoma/genética; Adulto; Anciano; Anciano de 80 o más Años; Animales; Fibroblastos Asociados al Cáncer/química; Fibroblastos Asociados al Cáncer/fisiología; Carcinoma de Pulmón de Células no Pequeñas/química; Carcinoma de Pulmón de Células no Pequeñas/genética; Carcinoma de Células Escamosas/química; Carcinoma de Células Escamosas/genética; Recuento de Células; Transdiferenciación Celular/efectos de los fármacos; Transdiferenciación Celular/genética; Neoplasias Colorrectales/patología; Progresión de la Enfermedad; Neoplasias Esofágicas/química; Neoplasias Esofágicas/genética; Femenino; Neoplasias de Cabeza y Cuello/química; Neoplasias de Cabeza y Cuello/tratamiento farmacológico; Neoplasias de Cabeza y Cuello/genética; Humanos; Neoplasias Pulmonares/química; Neoplasias Pulmonares/genética; Masculino; Ratones; Persona de Mediana Edad; Neoplasias de la Boca/patología; Miofibroblastos/química; NADPH Oxidasa 4; NADPH Oxidasas/análisis; NADPH Oxidasas/genética; Trasplante de Neoplasias; Neoplasias Orofaríngeas/patología; Fenotipo; Pirazoles/uso terapéutico; Pirazolonas; Piridinas/uso terapéutico; Piridonas; Interferencia de ARN; Especies Reactivas de Oxígeno/metabolismo; Tasa de Supervivencia; Regulación hacia Arriba

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Esofágicas / Neoplasias de la Boca / Carcinoma de Células Escamosas / Neoplasias Colorrectales / Adenocarcinoma / Neoplasias Orofaríngeas / Carcinoma de Pulmón de Células no Pequeñas / NADPH Oxidasas / Miofibroblastos / Fibroblastos Asociados al Cáncer Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Aged80 Idioma: En Revista: J Natl Cancer Inst Año: 2018 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google